| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.05. | Sangamo Therapeutics GAAP EPS of -$0.27 misses by $0.05, revenue of $0.48M misses by $5.88M | 16 | Seeking Alpha | ||
| 09.05. | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | 3 | SEC Filings | ||
| 09.05. | Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results | 116 | Business Wire | RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
"Sangamo... ► Artikel lesen | |
| 09.05. | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing | 231 | Business Wire | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale... ► Artikel lesen | |
| 25.03. | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | 36 | SEC Filings | ||
| 22.03. | Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall | 25 | Seeking Alpha | ||
| 22.03. | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | 562 | Business Wire | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| 13.03. | Sangamo Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 13 | Reuters | ||
| 13.03. | Sangamo Therapeutics GAAP EPS of -$0.34 misses by $0.08, revenue of $2.04M misses by $6.07M | 8 | Seeking Alpha | ||
| 13.03. | Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results | 141 | Business Wire | RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial... ► Artikel lesen | |
| 13.03. | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | 4 | SEC Filings | ||
| 13.03. | SANGAMO THERAPEUTICS, INC - 10-K, Annual Report | 3 | SEC Filings | ||
| 12.02. | Sangamo Therapeutics Reports U.S. And European Regulatory Support For ST-920 | 57 | RTTNews | ||
| 12.02. | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease | 802 | Business Wire | U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Biologics License Application (BLA)... ► Artikel lesen | |
| 06.02. | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | 14 | SEC Filings | ||
| 19.01. | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | 33 | SEC Filings | ||
| 19.01. | Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings) | 40 | Benzinga.com | ||
| 13.12.23 | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | 55 | SEC Filings |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 4.519 |
| TUI | 3.555 |
| EVOTEC | 3.219 |
| PLUG POWER | 2.613 |
| AMC ENTERTAINMENT | 2.293 |
| NEL | 1.839 |
| BAYER | 1.509 |
| SIEMENS ENERGY | 1.375 |
| RHEINMETALL | 1.348 |
| COMMERZBANK | 1.304 |
| ALLIANZ | 1.136 |
| NVIDIA | 1.099 |
| THYSSENKRUPP | 1.093 |
| RWE | 1.088 |
| AIXTRON SE | 1.004 |
| THYSSENKRUPP NUCERA | 974 |
| MERCEDES-BENZ | 971 |
| BYD | 868 |
| DEUTSCHE BANK | 866 |
| SUPER MICRO COMPUTER | 803 |
| RENK GROUP | 773 |
| VOLKSWAGEN | 745 |
| SFC ENERGY | 703 |
| NORDEX | 691 |
| TESLA | 665 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
